Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $571 From $606, Maintains Equal-Weight Rating

10/12/2021 | 09:45am EST


ę MT Newswires 2021
All news about REGENERON PHARMACEUTICALS
12/03Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
PR
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/02MarketScreener's World Press Review - December 2, 2021
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Yen, Swiss franc rally on global outlook risks after hawkish Powell
RE
11/30ANALYSIS : As Omicron plays havoc with markets, shares of vaccine makers surge
RE
11/30Wall St sinks as taper acceleration worries pile onto virus angst
RE
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash 2021 5 814 M - -
P/E ratio 2021 9,08x
Yield 2021 -
Capitalization 66 409 M 66 409 M -
EV / Sales 2021 3,93x
EV / Sales 2022 4,40x
Nbr of Employees 9 766
Free-Float 81,9%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 635,16 $
Average target price 697,52 $
Spread / Average Target 9,82%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS31.23%66 409
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819
BEIGENE, LTD.36.22%32 284